|Mr. James Henry Barder||CEO & Exec. Director||437.13k||N/A||1960|
|Ms. Angela Hildreth||COO, Fin. Director, Company Sec. & Exec. Director||354.33k||N/A||N/A|
|Mr. Kenneth William James||Head of R&D & Exec. Director||327.39k||N/A||1953|
|Dr. William Duncan Potter||Chief Scientific Officer & Adviser to the Board||N/A||N/A||1948|
|Graham Smith||Head of Alliance Partnerships & Supply||N/A||N/A||N/A|
|Kevin Langridge||Head of Quality||N/A||N/A||N/A|
Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
Futura Medical plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.